A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)
Summary
This study will evaluate safety, tolerability and effects on central diastolic blood pressure (cDBP) of MK-8892 given as single oral doses in healthy male participants (Panel A and B) and in male participants with mild-to-moderate hypertension (Panel C).
Timeline
- Start
- 2013-03-15
- Primary completion
- 2013-07-17
- Completion
- 2013-07-17
Outcome
Mixed primary results
registry analysis (other test); 6.0 mg MK-8892-Healthy vs Placebo-Healthy; p = 0.002; Difference in LS Means -4.89 NCT01798849 ↗
registry analysis (other test); 0.5 mg MK-8892-Healthy vs Placebo-Healthy; p = 0.732; Difference in Least-square (LS) Means -0.50 NCT01798849 ↗
registry analysis (other test); 2.0 mg MK-8892-Hypertensive vs Placebo-Hypertensive; p = 0.000; Difference in LS means -6.32 NCT01798849 ↗
registry analysis (other test); 0.5 mg MK-8892-Hypertensive vs Placebo-Hypertensive; p = 0.165; Difference in LS means -2.34 NCT01798849 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-8892 | Unknown | 0.5 mg | Oral |
| Subject | MK-8892 | Unknown | 1 mg | Oral |
| Subject | MK-8892 | Unknown | 2 mg | Oral |
| Subject | MK-8892 | Unknown | 4 mg | Oral |
| Subject | MK-8892 | Unknown | 6 mg | Oral |
| Subject | MK-8892 | Unknown | 9 mg | Oral |
| Subject | MK-8892 | Unknown | 12 mg | Oral |
| Subject | MK-8892 | Unknown | 14 mg | Oral |